My HPRA: Register

Lartruvo (olaratumab) - Important Safety Information from Eli Lilly & Company as approved by the HPRA

Notice type: 3rd Party Publications

Date: 31/01/2019

  

Problem Or Issue:
Important Safety Information communication from Eli Lilly & Company - Lartruvo (olaratumab): outcome of required post-approval study did not confirm the clinical benefit of olaratumab in the approved indication.

Important Safety Information - Lartruvo (olaratumab)
 

« Back